REACT-AF (Active/Enrolling)

• Evaluating standard of care with continuous DOAC versus time-limited DOAC therapy guided by an AF-sensing smartwatch in patients with a history of atrial fibrillation and low-to-moderate stroke risk.

Left vs Left (Active/Enrolling)

• Comparing the effectiveness of His bundle pacing versus left bundle branch pacing on patient-centered outcomes.

SIMPLAAFY (Active/Enrolling)

• Assessing the safety and effectiveness of two monotherapy regimens compared to dual antiplatelet therapy (DAPT) following implantation of the WATCHMAN FLX Pro device.

Real AF (Active/Enrolling)

• Capturing real-world data on catheter ablation for symptomatic paroxysmal and persistent AF using novel CARTO technologies.

Preference (Active/Enrolling)

• Evaluating the relative importance of anticoagulant treatment attributes from the perspective of AF patients and their treating physicians.

Conform (Active/Enrolling)

• Assessing the safety and effectiveness of the CLAAS device in comparison to existing LAAO systems for patients with non-valvular atrial fibrillation.

Librexia (Follow-up)

• Evaluating whether milvexian is non-inferior to apixaban in preventing stroke and non-CNS systemic embolism.

Laminar LAAX (Pending)

• Comparing the safety and effectiveness of the Laminar System to commercially available LAAC devices (e.g., Watchman FLX, Amulet) in patients with non-valvular AF who are candidates for LAAC.

Prevail (Pending)

• Investigating the Prevail Drug-Coated Balloon in patients with in-stent restenosis, and in a single-arm study for de novo lesions in small vessel disease.

ALLAY-HF (Active/Enrolling)

• Evaluating the safety and efficacy of the Alleviant ALV1 system in patients with chronic HF with preserved or mildly reduced EF who remain symptomatic despite guideline-directed medical therapy.

HERMES (Active/Enrolling)

• Studying the effects of ziltivekimab versus placebo on morbidity and mortality in patients with HFpEF or HFmrEF and systemic inflammation.

REDEFINE HF (Active/Enrolling)

• Evaluating finerenone’s efficacy and safety on morbidity and mortality in patients with left ventricular ejection fraction greater or equal to 40% hospitalized due to acute decompensated Heart Failure.

CONFIRMATION HF (Active/Enrolling)

• Investigating the combined efficacy and safety of early, intensive management using finerenone and an SGLT2 inhibitor in hospitalized Heart Failure patients.

ALLAY-HFrEF (Active/Enrolling)

• Assessing the safety and efficacy of the Alleviant no-implant interatrial shunt in patients with heart failure and reduced ejection fraction.

COMET HF (Active/Enrolling)

• Evaluating the efficacy and safety of Omecamtiv Mecarbil in patients with symptomatic Heart Failure and severely reduced Ejection Fraction.

Cardiosounds (Pending)

Observational study of the CardioSounds sensor for hemodynamic monitoring

• In patient hospitalized with acutely decompensated heart failure and implanted with a pulmonary artery catheter.
• In patients undergoing de novo implantation of the CardioMEMS pulmonary artery pressure sensor.

Optimizer PAS (Pending)

• Open-label study of patients receiving the OPTIMIZER implant as part of standard care.

COMPLETE TAVR (Active/Enrolling)

• To determine whether, on a background of guidelines-directed medical therapy, a strategy of complete revascularization involving PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to strength of medical therapy alone in reducing the composite outcome of cardiovascular death, new myocardial infarction, ischemia-driven revascularization, or hospitalization for unstable angina or hospitalization for heart failure in patients selected to undergo elective transfemoral TAVR with a balloon expandable transcatheter heart valve.

Empower (Active/Enrolling)

• Evaluating the safety of deploying and implanting the Carillon device in the coronary sinus/great cardiac vein for patients with functional mitral regurgitation.